Contineum Therapeutics, Inc. (CTNM) SEC Filings & Earnings Calls
EquiReason read 11 Contineum Therapeutics, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-14 — Contineum Therapeutics reported results from MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 for major depressive disorder..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 312.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
14 Sep 20268-K · 8.01Contineum Therapeutics reported results from MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 for major depressive disorder.open
Risks flagged
Clinical trial outcome unknown; potential for negative results affecting partnership with J&J.
“No specific data provided in the filing; reliance on press release for details.”
30 Jul 202610-QQuarterly net loss improved slightly; no revenue; key clinical milestones achieved.earningsopen
Figures in the filing · each found in the filing text
| Net Loss · Q2-2026 | $-15M | |
| Cash, Cash Equivalents and Marketable Securities · 2026-06-30 | $237M | |
| Research and Development Expenses · Q2-2026 | $13M | -10% y/y |
| Accumulated Deficit · 2026-06-30 | $207M |
Risks flagged
Funding Dependency
“If events or circumstances occur such that we do not obtain additional funding, we may need to delay, reduce or eliminate our product development or future commercialization efforts.” · word for word
Clinical Trial Risk
“The successful development of our drug candidates is highly uncertain.” · word for word
No Revenue
“We do not have any products approved for sale and we have not yet generated any revenue from product sales.” · word for word
30 Jul 20268-K · 2.02Contineum Therapeutics reports Q2 2026 net loss of $15.2M vs $16.0M year ago; cash $236.6M; affirms clinical milestones; workforce reduction in research team.earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · 2026-06-30 | $237M | |
| Research and development expenses · Q2-2026 | $13M | -10% y/y |
| General and administrative expenses · Q2-2026 | $5M | +23% y/y |
| Net loss · Q2-2026 | $-15M |
Risks flagged
Workforce reduction and CSO departure may indicate pipeline prioritization challenges.
“Streamlined discovery programs resulted in limited workforce reduction and departure of Chief Scientific Officer.”
13 Jul 20268-K · 7.01Contineum Therapeutics updates corporate presentation with business and strategic updates. No material new information; forward-looking statements and risk factors.open
Risks flagged
No material new information; presentation contains standard forward-looking statements and risk factors.
“Corporate presentation update with no new material events.”
5 May 202610-QContineum reported Q1 2026 results: PIPE-307 Phase 2 RRMS trial failed endpoints; PIPE-791 chronic pain trial met primary endpoint; cash position $246.3M.open
Figures in the filing · each found in the filing text
| Net loss · Q1-2026 | $-14M | |
| Operating cash flow · Q1-2026 | $-16M | |
| Free cash flow · Q1-2026 | $-17M |
Risks flagged
Clinical trial failure risk
“The trial did not meet its prespecified primary and secondary efficacy endpoints.” · word for word
Dependence on J&J for PIPE-307
“J&J has sole discretion whether or not to further develop PIPE-307 for RRMS, MDD, or any other indication.” · word for word
Funding risk
“We expect to finance our operations through both public and private sales of equity, debt financings or other commercial arrangements.” · word for word
5 May 20268-K · 2.02Contineum reports positive topline Phase 1b data for PIPE-791 in chronic pain; trial met safety objective, pain improvements numerically greater than placebo. Also affirms IPF Phase 2 enrollment and cash runway through mid-2029.open
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q1-2026 | $246M | |
| Research and development expenses · Q1-2026 | $12M | -15% y/y |
| General and administrative expenses · Q1-2026 | $5M | +20% y/y |
| Net loss · Q1-2026 | $-15M | -9% y/y |
Risks flagged
Heavy dependence on early-stage pipeline (PIPE-791 and PIPE-307); clinical and regulatory risks.
“the Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development” · word for word
Cash burn rate; net loss of $14.5M in Q1 2026.
“Net loss was $14.5 million for the three months ended March 31, 2026” · word for word
30 Apr 2026DEF 14AAnnual proxy statement for 2026 annual meeting; no material event disclosed.open
Risks flagged
Clinical-stage biotech risk
“We are eligible to receive approximately $1.0 billion in non-refundable, non-creditable milestone payments.”
Dependence on J&J partnership
“J&J is generally responsible for all development, manufacturing, and commercialization activities for PIPE-307.” · word for word
Inducement grant risk
“Represents stock options granted to Dr. Watkins on April 28, 2025 outside of the 2024 Plan pursuant to the inducement grant exception” · word for word
5 Mar 202610-KAnnual report (10-K) for FY2025 detailing clinical trial results: PIPE-307 failed Phase 2 in RRMS, PIPE-791 Phase 2 in IPF initiated, and chronic pain trial completed enrollment.earningsopen
Risks flagged
PIPE-307 Phase 2 failure in RRMS
“In November 2025, we reported top-line data from our Phase 2 VISTA trial of PIPE-307 for the treatment of patients with RRMS. The trial did not meet its prespecified primary and secondary efficacy endpoints.” · word for word
Dependence on early-stage pipeline
“We are heavily dependent on the success of PIPE-791, our lead drug candidate, and PIPE-307, both of which are in the early stages of clinical development.” · word for word
Funding risk for deferred programs
“In 2025, we made a strategic decision to defer further clinical development of our PIPE-791 PrMS program and to defer the initiation of clinical development for our CTX-343 program until funding is obtained to specifically move these programs forward.” · word for word
5 Mar 20268-K · 2.02, 8.01Contineum Therapeutics amended its at-the-market (ATM) sales agreement to increase the aggregate offering price from $75M to $100M, filed a new prospectus supplement, and reported Q4 2025 financial results.open
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q4-2025 | $263M | |
| Research and development expenses · Q4-2025 | $13M | -2% y/y |
| General and administrative expenses · Q4-2025 | $4M | +8% y/y |
Risks flagged
Potential dilution from increased ATM facility and recent public offering.
“Amendment to increase aggregate offering price from $75M to $100M; recent public offering of 8.1M shares at $12.25.”
Clinical trial execution risk for Phase 2 IPF trial and Phase 1b chronic pain trial.
“Phase 2 PROPEL-IPF trial recently initiated; Phase 1b chronic pain trial topline data expected Q2 2026.”
30 Oct 20258-K · 2.02Contineum Therapeutics reported Q3 2025 financial results with net loss of $12.8M, cash of $182.4M, and extended cash runway through 2028. Key clinical milestones affirmed: PIPE-307 Phase 2 VISTA topline data expected Q4 2025, PIPE-791 Phasearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q3-2025 | $182M | |
| Net loss · Q3-2025 | $-13M | +24% y/y |
| Research and development expenses · Q3-2025 | $11M | +13% y/y |
| General and administrative expenses · Q3-2025 | $4M | +21% y/y |
| Net proceeds from ATM offerings · Q3-2025 | $19M | |
| Shares issued in ATM offerings · Q3-2025 | 3,200,000 | |
| Weighted average price per share in ATM · Q3-2025 | $6.04 |
Risks flagged
Clinical trial outcomes remain binary risk; PIPE-307 VISTA topline data expected Q4 2025.
“Topline data from PIPE-307 Phase 2 VISTA trial expected Q4 2025.”
Increased net loss and operating expenses indicate cash burn acceleration.
“Net loss $12.8M vs $10.3M prior year; R&D +13%, G&A +21%.”
Dependence on key pipeline programs; deferral of other programs reduces diversification.
“Deferred initiation of PIPE-791 PrMS and CTX-343 programs.”
30 Oct 202510-QQ3 2025 net loss increased to $12.8M from $10.3M in Q3 2024; no revenue; cash position $182.4M.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q3-2025 | $-13M | |
| Cash and cash equivalents and marketable securities · 2025-09-30 | $182M | |
| Operating cash flow · 9M-2025 | $-42M |
Risks flagged
Clinical-stage company with no approved products or revenue
“We do not have any products approved for sale and we have not yet generated any revenue from product sales.” · word for word
Dependence on additional financing
“If events or circumstances occur such that we do not obtain additional funding, we may need to delay, reduce or eliminate our product development or future commercialization efforts.” · word for word
Contineum Therapeutics, Inc. — questions
- What did Contineum Therapeutics, Inc. file recently?
- 11 SEC filings in the last 12 months. Latest: 8-K on 2026-09-14 — Contineum Therapeutics reported results from MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 for major depressive disorder.
Every figure on this page comes from Contineum Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.